Under neuroinflammatory conditions, such as multiple sclerosis (MS), tumor necrosis factor receptor-1 (TNFR1) is believed to mediate the pro-inflammatory activities associated with tumor necrosis factor (TNF), while tumor necrosis factor receptor-2 (TNFR2) may induce anti-inflammatory effects and promote remyelination and neuroprotection (Fontaine et al., 2002; Fischer et al., 2020). Here, TNFRSF1B is linked to myeloid sarcoma.